The GLP-1 Pill War Has a Clear Early Winner and It Isn't Lilly

When Novo Nordisk reported first-quarter earnings on Wednesday, the headline number that moved markets was not the company's overall revenue figure. It was a single product line: the Wegovy pill, which generated 2.26 billion Danish kroner, or roughly $354 million, in its first full quarter on the market. That figure was nearly double what analysts had expected. Jefferies analyst Michael Leuchten had penciled in 1.16 billion kroner. The actual number was almost twice that. For a company that spent much of the past year in retreat, laying off 9,000 workers, installing a new CEO, and watching its next-generation pipeline stumble, the Wegovy pill's launch is the most important piece of good news Novo has had in a long time.

The broader context matters. Novo Nordisk entered 2026 in a difficult position. Its experimental combination obesity shot CagriSema failed to match Eli Lilly's Zepbound in a head-to-head study released in February. Its stock had been under sustained pressure. The company guided investors in February to expect full-year adjusted sales and operating profit to shrink by 5% to 13%. On Wednesday, it revised that guidance to a decline of just 4% to 12%, a modest improvement but a meaningful signal that the pill launch is tracking ahead of plan. Overall adjusted sales and operating income beat Wall Street expectations by 1% and 14% respectively, according to Leuchten. The stock responded positively, and for good reason: this is a company that needed a win, and the Wegovy pill is delivering one.

The Prescription Gap That Has Lilly Investors Nervous

The more consequential number in Novo's earnings report, from a competitive standpoint, is the prescription count. More than 2 million prescriptions have now been written for the Wegovy pill since its January 5 launch. In its first full week on the market, the drug generated more than 18,000 prescriptions. Compare that to Eli Lilly's Foundayo, the oral version of its GLP-1 drug that received FDA approval on April 1 and launched on April 9: Foundayo generated just 5,612 prescriptions in its third week after launch, according to Reuters data. That is not a close race. Novo has a commanding early lead in the oral GLP-1 market, and the gap is wide enough to have triggered genuine concern among Lilly investors about how quickly Foundayo can build a prescription base.

Lilly CEO David Ricks has pushed back on the comparison, arguing that Foundayo is a genuinely new molecule rather than an oral version of an existing injectable drug, and that new molecules typically take longer to build prescriber familiarity. He told CNBC recently that almost all the people who started on the Wegovy pill were trying a GLP-1 medicine for the first time, which he sees as evidence that the oral market is expanding rather than cannibalizing injectables. That is a reasonable argument, and it may prove correct over time. But in the near term, the prescription data is what it is, and it favors Novo.

The Clinical Picture Is More Complicated

The prescription gap does not tell the whole story. In clinical trials, patients on the Wegovy pill lost a higher percentage of body weight than those in Lilly's testing of Foundayo. That would seem to favor Novo. But the two drugs have not been evaluated head-to-head, which means the comparison is imperfect. Lilly's counterargument is convenience: Foundayo can be taken any time of day without restrictions on food or water, while oral Wegovy must be swallowed first thing in the morning on an empty stomach, 30 minutes before eating or drinking anything else. For a daily pill that patients will take for years, that distinction matters. Adherence is one of the central challenges in obesity treatment, and a drug that fits more easily into a morning routine has a real-world advantage that clinical trial data does not capture.

Both companies have priced their starter doses at $149 per month for self-pay patients, matching each other exactly. Both have online pharmacies with free shipping. Amazon Pharmacy sells both and has same-day delivery available in nearly 3,000 cities. The commercial infrastructure is essentially identical. The differentiation will come down to efficacy perception, convenience, and the prescriber relationships each company builds over the next 12 to 18 months.

The Medicare Catalyst Nobody Is Fully Pricing In

The most significant near-term catalyst for both companies is not the head-to-head prescription battle. It is Medicare. Starting July 1, Medicare coverage for GLP-1 obesity drugs expands substantially, a development that could add millions of eligible patients to the addressable market almost overnight. Both Novo and Lilly agreed to lower their prices for Medicare as part of a government deal to avoid pharmaceutical tariffs, and co-pays for Medicare patients may be as little as $50 per month for the starter dose. The scale of the Medicare expansion is difficult to overstate: there are approximately 65 million Medicare beneficiaries, and obesity affects a significant portion of that population. Even a modest penetration rate would represent a massive volume increase for both companies.

The question for investors is which company is better positioned to capture that Medicare expansion. Novo has the prescription momentum and the brand recognition of Wegovy, which has been on the market in injectable form since 2021. Lilly has the superior injectable product in Zepbound, which holds roughly 60% of the GLP-1 market, and the convenience argument for Foundayo. Both companies have agreed to the Medicare pricing terms. The July 1 date is a hard catalyst that will generate real prescription data, and that data will go a long way toward resolving the current uncertainty about how the oral market shakes out.

What the GLP-1 War Means for the Broader Healthcare Sector

The Novo earnings report is a useful reminder that the GLP-1 story is not just about two companies. It is reshaping the entire healthcare investment landscape. Insurers are grappling with coverage decisions that could add billions to their medical cost ratios. Pharmacy benefit managers are negotiating formulary positions that will determine which pill gets preferred status. Medical device companies that make equipment for obesity-related conditions are watching their addressable markets shrink as patients lose weight. Food companies are already seeing the behavioral effects of GLP-1 use show up in their sales data. A Deutsche Bank analysis found that GLP-1 users go to restaurants half as often as before starting the drugs, while spending slightly more per visit. The ripple effects are everywhere.

For the moment, Novo has the better story in the oral market. Its pill launched first, its prescription numbers are stronger, and its Q1 earnings beat gave management the credibility to raise guidance. Lilly still dominates the injectable market and has the deeper pipeline, with its triple-acting retatrutide drug showing strong Phase 3 results in diabetes and osteoarthritis. The oral battle is early, the Medicare expansion is coming, and the market is large enough for both companies to win. But right now, in the first quarter of the pill era, Novo is ahead.